.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,214,506

« Back to Dashboard
Patent 7,214,506 protects JUBLIA and is included in one NDA.

This patent has eleven patent family members in eleven countries.

Summary for Patent: 7,214,506

Title:Method for treating onychomycosis
Abstract: A novel method for evaluating an effect of an antimicrobial agent which comprises removing the antimicrobial agent remaining in a biological sample or the like to thereby accurately evaluate the effect of the antimicrobial agent without being affected by the remaining antimicrobial agent. A therapeutic agent for onychomycosis which can be obtained according to the evaluation method of the drug effect.
Inventor(s): Tatsumi; Yoshiyuki (Otsu, JP), Yokoo; Mamoru (Otsu, JP), Nakamura; Kosho (Moriyama, JP), Arika; Tadashi (Suita, JP)
Assignee: Kaken Pharmaceutical Co., Ltd. (Bunkyo-ku, Tokyo, JP)
Application Number:10/685,266
Patent Claim Types:
see list of patent claims
Use;
Patent Metrics:
Source: PatentQuant.com
Field: Biotechnology
Back Citations: 8th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Dow Pharm
JUBLIA
efinaconazole
SOLUTION;TOPICAL203567-001Jun 6, 2014RXYes7,214,506► subscribe ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,214,506

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan11/214369Jul 28, 1999

International Patent Family for Patent: 7,214,506

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria434667► subscribe
Australia5852400► subscribe
Canada2391274► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc